Summary:
A massive meta-analysis spanning nearly 16 million individuals across three continents reveals that people diagnosed with ADHD have a 70% higher rate of death from all causes compared to those without the condition. The increased mortality is driven by heightened risks of suicide, accidental injuries, and natural causes, though preliminary evidence suggests that ADHD medication is associated with a 25% reduction in overall mortality risk.
Key Facts:
- 70% Higher All-Cause Mortality: Across 19 longitudinal studies tracking participants for up to 20 years, an ADHD diagnosis was associated with a 70% increase in all-cause mortality compared to non-ADHD controls.
- Disproportionate Risk Drivers: Mortality rates among individuals with ADHD were 90% higher for suicide, 55% higher for intentional and unintentional injuries, and 27% higher for natural-cause deaths (such as cardiovascular and metabolic disease).
- Protective Effect of Medication: Analysis of available treatment data revealed that people with ADHD who took prescribed medications experienced a 25% lower mortality risk, emphasizing the urgent need for timely diagnosis and sustained treatment support.
Source: University College London (UCL) / University of Liverpool
Attention-deficit/hyperactivity disorder (ADHD) is widely recognized as a neurodevelopmental condition characterized by challenges with sustained attention, executive function, and impulse control. While its cognitive and educational consequences are well established, emerging epidemiological data shows that its health ramifications can be far more serious.
In a comprehensive systematic review and meta-analysis published in JAMA Network Open, researchers from University College London (UCL) and the University of Liverpool analyzed data from 19 longitudinal cohort studies encompassing close to 16 million participants across three continents. In some included cohorts, individuals were monitored for more than two decades.
The findings deliver a sobering look at the long-term health inequalities associated with the neurodivergent condition: individuals with an ADHD diagnosis had a 70% higher rate of death from all causes compared to those without the diagnosis.
Mapping the Causes of Premature Mortality
The elevated mortality associated with ADHD spanned both unnatural and natural causes, reflecting a mix of behavioral, psychiatric, and physical health challenges:
- Suicide (90% Increase): Suicide mortality was nearly double among individuals with ADHD, driven by higher rates of comorbid depression, emotional dysregulation, and impulsive behaviors during acute crises.
- Injuries (55% Increase): Deaths from intentional and unintentional injuries, including motor vehicle crashes, falls, and fatal accidents, were elevated, likely connected to inattention, distractibility, and elevated risk-taking tendencies.
- Natural Causes (27% Increase): Death from physical illnesses was significantly higher, driven by elevated rates of cardiovascular disease, type 2 diabetes, metabolic syndrome, and cancer.
“We have previously found that people with ADHD have reduced life expectancies, so here we are adding to our understanding of what drives this very concerning statistic,” said senior author Joshua Stott, PhD, professor in UCL Psychology and Language Sciences. “We found that people with ADHD face an increased risk not only of death by suicide and injury, but also of deaths by natural causes, adding to evidence that health inequalities faced by people with ADHD are broad and wide-ranging.”
The researchers noted that excess natural-cause mortality is frequently compounded by lifestyle risk behaviors, including tobacco, alcohol, and substance use, as well as systemic barriers to healthcare engagement, difficulty scheduling appointments, and reduced adherence to chronic disease regimens.
The Protective Potential of Pharmacotherapy
Despite the stark mortality statistics, the researchers found a promising signal when examining treatment interventions. Among individuals diagnosed with ADHD, those who were prescribed ADHD medication exhibited an estimated 25% reduction in all-cause mortality compared to untreated peers.
While promising, the investigators caution that this protective effect was drawn from three of the 19 studies that specifically tracked medication status, meaning further targeted investigation is needed.
“Our findings provide early evidence to suggest that medication may play an important role in supporting the health of people with ADHD, but this is based on a small number of studies and further research is needed to clarify this link,” said first author Lucy Corrigan of the University of Liverpool. “And medication is just part of the story; many people with ADHD benefit from comprehensive, long-term treatment and support.”
Closing the Diagnostic Gap
The research team stressed that ADHD itself is not inherently fatal, and that the elevated mortality risk largely reflects modifiable environmental, societal, and treatment deficits.
“ADHD is not by definition a life-limiting condition as the right support and treatment can help people with ADHD to live long and healthy lives,” emphasized Stott. “Our findings underscore the importance of ensuring that everyone who may have ADHD has access to accurate diagnosis and treatment. While ADHD diagnosis rates have risen in recent years, they may still lag behind actual prevalence, particularly for older age groups where mortality risk may be most pertinent.”
Senior author Amber John, PhD, of UCL and the University of Liverpool, added that addressing systemic healthcare disparities must remain a central public health priority: “Many people with ADHD face challenges throughout their lives, so equitable access to evidence-based assessment and treatment is vital to ensure they can live long, healthy lives.”
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this ADHD disease Research:
- Media Contact: Alexandra Middleton
- Source: UCL
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: JAMA Network Open (Oct 19, 2026). “Mortality among people with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis.” Authors: Lucy Corrigan, BSc; Lauren Heywood, MSc; Gavin R. Stewart, PhD; Elizabeth O’Nions, PhD; Henry Shelford, MSc; Joshua Stott, PhD; and Amber John, PhD.
- DOI: 10.1001/jamanetworkopen.2026.39448
Abstract
Mortality among people with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis
Importance
Attention-deficit/hyperactivity disorder (ADHD) is associated with adverse life outcomes and increased mortality. Clarifying the magnitude of mortality risks using international data and the potential association between medication and mortality is essential to inform clinical care and motivate public health strategies to address mortality.
Objectives
To examine the association between ADHD and all-cause and cause-specific mortality and to assess whether mortality risk differs according to ADHD medication use.
Data Sources
A comprehensive search of PubMed, Web of Science, PsycINFO, EMBASE, MEDLINE, and CINAHL was conducted from database inception to July 8, 2025.
Study Selection
Eligible studies included quantitative research across all age groups reporting all-cause and/or cause-specific mortality in individuals with ADHD, defined via diagnostic criteria, self-identification, trait measures, or ADHD polygenic risk scores. Exclusion criteria were nonoriginal research, qualitative studies, non–peer-reviewed publications, and studies not reporting mortality outcomes.
Data Extraction and Synthesis
Data extraction was conducted independently by 2 reviewers. Study quality was assessed by 1 reviewer. Summary data were extracted from published reports, and pooled hazard ratios (HRs) were calculated using random-effects model meta-analysis.
Main Outcomes and Measures
The primary outcomes were all-cause mortality and cause-specific mortality (suicide, unintentional or intentional injury, and natural causes), measured using HRs with 95% CIs.
Results
Nineteen studies including 15 920 970 participants (36.1% female) were included. ADHD was associated with increased all-cause mortality (HR, 1.71; 95% CI, 1.31-2.24; P < .001). Significant associations were also observed for suicide (HR, 1.89; 95% CI, 1.21-2.95; P = .005), unintentional or intentional injury (HR, 1.55; 95% CI, 1.22-2.00; P < .001), and natural-cause mortality (HR, 1.27; 95% CI, 1.16-1.38; P < .001). ADHD medication use in people with ADHD was associated with reduced all-cause mortality (HR, 0.75; 95% CI, 0.64-0.87; P < .001). Substantial heterogeneity was observed across studies.
Conclusions and Relevance
In this systematic review and meta-analysis of ADHD and mortality, ADHD was associated with increased mortality across multiple causes; and ADHD medication was associated with a decreased all-cause mortality risk, underscoring the importance of timely diagnosis and treatment. However, the heterogeneity observed across studies highlights the need for standardized methods and improved control of confounding factors to better characterize mortality risk among individuals with ADHD.
